Ocular Therapeutix (OCUL) Operating Leases (2019 - 2026)

Ocular Therapeutix's Operating Leases history runs 8 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 13.07% year-over-year to $4.2 million in Q1 2026; TTM through Mar 2026 was $4.2 million, a 13.07% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 47.33% from the prior year.
• Operating Leases climbed to $4.2 million in Q1 2026 per OCUL's latest filing, from $2.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $8.7 million in Q4 2022 and bottomed at $2.8 million in Q4 2025.
• The 5-year median for Operating Leases is $5.5 million (2022), against an average of $5.7 million.
• Across the five-year window, Operating Leases jumped 57.29% in 2023 and tumbled 47.33% in 2025, its largest moves.
• Year by year, Operating Leases stood at $8.7 million in 2022, then retreated by 20.74% to $6.9 million in 2023, then slipped by 22.29% to $5.3 million in 2024, then tumbled by 47.33% to $2.8 million in 2025, then soared by 50.27% to $4.2 million in 2026.
• Per Business Quant, the three latest OCUL Operating Leases figures stand at $4.2 million (Q1 2026), $2.8 million (Q4 2025), and $3.6 million (Q3 2025).